Par Nijhawan, CEO of Edesa Biotech, shares his thoughts on the recent BARDA announcement and what this means for the Company moving forward. $EDSA

Edesa Biotech today reported #financialresults for the 3rd quarter of FY 2024 #vitiligo #dermatitis #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

Edesa Biotech will be participating in #BIOEurope next week, Nov 4-6. Reach out to our team ahead of the event in the partnering system or at edesabiotech.com/about/contact-… #vitiligo #fibrosis #ARDS #dermatitis

$EDSA announced today that the company’s CEO & Founder, Dr. Par Nijhawan, will invest up to $5 million in Edesa, including an immediate investment of ~$1.5 million. >> globenewswire.com/news-release/2… #vitiligo #ACD #ARDS #fibrosis #biotech

Edesa Biotech today reported #financialresults for FY 2024 #vitiligo #ACD #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

Edesa Biotech Announces $15m private placement led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders. globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresultsfor fiscal 1Q 2025 #vitiligo #ACD #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

Congratulations to the Global #Vitiligo Foundation for hosting a great scientific symposium this week at #AAD2025. Edesa is proud to provide support for advancing research, education and collaboration within the vitiligo community.

Edesa is pleased to announce that Peter Weiler will assume the role of CFO on May 1. Peter is a veteran of the #pharma and #biotech sectors, with extensive experience in finance and corporate strategy. globenewswire.com/news-release/2…

Edesa to join the annual Bloom Burton Healthcare Investor #Conference next week. $EDSA #vitiligo #BBHIC2025 globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresults for fiscal 2Q 2025 $EDSA globenewswire.com/news-release/2…

Edesa Biotech is a proud sponsor and supporter of World #Vitiligo Day and this year’s theme “Innovation for Every Skin” #WVD2025 #biotechnology #CXCL10 $EDSA worldvitiligoday.ca

Edesa Biotech today reported #financialresults for fiscal 3Q 2025 $EDSA globenewswire.com/news-release/2…

Edesa to participate in the H.C. Wainwright & Co. 27th Annual Global Investment Conference next week in New York #HCWConference #vitiligo #ARDS $EDSA

Edesa’s #Phase3 study of paridiprubart in patients with #ARDS met its primary and secondary endpoints, showing demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. $EDSA #biotech #drugdevelopment nasdaq.com/press-release/…

Edesa Biotech today reported #financialresults for fiscal year 2025 $EDSA globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresults for fiscal 1Q 2026 $EDSA #vitiligo #ARDS globenewswire.com/news-release/2…

Additional clinical data from Edesa’s #Phase3 study affirmed statistically significant mortality reductions in the full population of 278 patients. Exploratory analysis also demonstrated reduced mortality in #AKI, #sepsis and #pneumonia. globenewswire.com/news-release/2…

Edesa Biotech advances #vitiligo clinical development program, selects JSS Medical Research as CRO for planned Phase 2 study. globenewswire.com/news-release/2… $EDSA #dermatology #AAD2026

Edesa is pleased to announce that our CEO, Dr. Par Nijhawan, has been selected to deliver the inaugural presentation at the #RIS2026 Oral Showcase at #ATS2026 #ARDS $EDSA globenewswire.com/news-release/2…